Opinion

Video

Addressing Vaccine Fatigue

Author(s):

Ryan Haumschild, PharmD, MS, MBAWanda Filer, MD, MBA

Mary Bridgeman, PharmD, BCPS, BCGP, discusses how providers and healthcare workers can address vaccine fatigue in patients eligible for the RSV vaccine.

Video content above is prompted by the following question:

  • How can providers and healthcare workers address vaccine fatigue in eligible patients?
Related Videos
A panel of 4 experts on CLL
A panel of 4 experts on CLL
A panel of 4 experts on lung cancer
A panel of 4 experts on breast cancer
A panel of 4 experts on lung cancer
A panel of 4 experts on CLL
A panel of 4 experts on CLL
Related Content
RSV swab test with negative result | Image credit: MargJohnsonVA - stock.adobe.com
September 4th 2024

RSV Vaccine Shows High Effectiveness Against Hospitalization in Older Adults

Pearl Steinzor
The first real-world study highlights benefits for adults aged 60 years and older who receive the respiratory syncytial virus (RSV) vaccine.
RSV vaccine vial with syringe - Respiratory syncytial virus shot | MargJohnsonVA - stock.adobe.com
August 30th 2024

Sixty Percent of Adults Over 50 Unaware of RSV Risks, Survey Reveals

Pearl Steinzor
A new survey highlights lack of awareness about respiratory syncytial virus (RSV) among older adults, posing increased health risks for those with chronic conditions.
Young child sneezing | Image credit: kornnphoto - stock.adobe.com
August 29th 2024

Impact of New York State's Paid Family Leave on Infant Respiratory Infections

Pearl Steinzor
An 18% reduction in acute care encounters for respiratory tract infections among infants 8 weeks or younger was identified following the implementation of New York's paid family leave policy.
Pediatrics | Image Credit: © Viacheslav Yakobchuk - stock.adobe.com
August 22nd 2024

Pediatric Primary Care, Emergency Visits for RSV Vary Greatly Worldwide

Christina Mattina
A recent study estimates the prevalence of primary care and emergency department visits by young children to treat respiratory syncytial virus (RSV), finding that the rates vary widely by country.
Pfizer | Image credit: jetcityimage - stock.adobe.com
August 15th 2024

Pfizer Reports Positive Phase 3 Results for RSV Vaccine in Immunocompromised Adults

Pearl Steinzor
The respiratory syncytial virus (RSV) vaccine shows strong immunogenicity and safety in immunocompromised adults, study finds.
Headquarters of the CDC | Imaged credit: Tada Images - stock.adobe.com
August 7th 2024

Updated ACIP Guidelines: RSV Vaccine for Adults Aged 60 Years and Older

Pearl Steinzor
CDC’s Advisory Committee on Immunization Practices (ACIP) revises respiratory syncytial virus (RSV) vaccination guidelines to prioritize older adults and those at higher risk of severe disease.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo